Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Lilly

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Robert J. Heine, M.D., Ph.D., F.R.C.P., will join Eli Lilly and Co. in January, 2008, as executive medical director for the diabetes and endocrine division responsible for development of Lilly’s expanding diabetes and obesity R&D portfolio. Dr. Heine replaces Dr. Meng Hee Tan, who will retire at the end of September after 8 years of service to the company.

“Lilly has a growing and exciting diabetes and obesity R&D portfolio that demands exceptional clinical leadership to guide and successfully develop,” said Vince Mihalik, vice president and global brand development platform leader, diabetes, obesity and endocrine. “Robert is widely recognized and respected in the diabetes community for his scientific and clinical excellence and his considerable leadership abilities. He’ll be a fantastic addition to the Lilly team.”

Dr. Heine is currently professor of diabetology in the Department of Endocrinology and director of the Diabetes Centre at the VU (Vrije Universiteit) University Medical Center in Amsterdam, Netherlands. He also holds positions within the European Association for the Study of Diabetes (EASD), the European Foundation for the Study of Diabetes (EFSD) and the American Diabetes Association (ADA), including chair of the EASD subcommittee for Clinical Research Training, president of the organizing committee for the 2007 EASD annual meeting, and a member of the ADA Expert Committee on guidelines for the treatment of hyperglycemia in type 2 diabetes. Dr. Heine’s primary research interests include the epidemiology and pathophysiology of type 2 diabetes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters